The point of care poc coagulation testing market has seen considerable growth due to a variety of factors.
• In recent times, the market size for point-of-care (POC) coagulation testing has shown significant growth. Its forecast projects an increase from $1.18 billion in 2024 to $1.25 billion in 2025, with a compound annual growth rate (CAGR) of 5.8%.
This growth in the historic period is due to several factors including higher patient demand, the increasing popularity of point-of-care testing, impressive reliability of coagulation status on pt test, combined with automation and integration with electronic health records (EHRs), as well as the growing incidence of cardiovascular diseases and blood disorders.
The point of care poc coagulation testing market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for point-of-care (POC) coagulation testing is anticipated to undergo consistent expansion in the upcoming years. The projected value by 2029 is $1.48 billion, achieving a compound annual growth rate (CAGR) of 4.2%.
This growth during the forecast period can be tied to an increase in healthcare applications, higher use in homecare environments, a rise in chronic blood diseases, patient preference for quick and precise testing, along with an increase in point-of-care testing. Key patterns for the forecast period encompass technological progress, increased demand in developed nations, further expanded use in healthcare, the impact of COVID-19, and growth in multiplexing POC diagnostics.
The escalating rates of cardiovascular disorders are projected to impel the expansion of the point-of-care (POC) coagulation testing market in the future. Cardiovascular illnesses consist of a variety of heart and blood vessel-related conditions, including coronary artery malady, cerebrovascular disorder, and peripheral arterial disorder. POC coagulation testing is beneficial in handling cardiovascular ailments as it offers real-time data about the coagulation condition, facilitating immediate determinations on coagulation actions and reducing bleeding complications post-heart surgery. For example, a study from the World Heart Federation, a Swiss non-governmental entity, in October 2022 stated that cardiovascular ailment mortality is projected to rise, estimating the number of deaths due to cardiovascular ailments to escalate from about 18.9 million in 2020 to over 22.2 million by 2030, and reach 32.3 million by 2050. Thus, the surging incidence of cardiovascular disorders is contributing to the growth of the POC coagulation testing market.
The point-of-care (POC) coagulation testing market covered in this report is segmented –
1) By Technology: Optical Technology, Mechanical Technology, Electrochemical Technology
2) By Distribution Channel: Direct Tenders, Retail
3) By End-User: Hospitals, Clinics, Home care
Subsegments:
1) By Optical Technology: Reflectance Photometry, Fluorescence Detection, Colorimetric Detection
2) By Mechanical Technology: Mechanical Oscillation, Ultrasonic Detection
3) By Electrochemical Technology: Amperometric Detection, Potentiometric Detection, Conductometric Detection
Key companies in the point-of-care (POC) coagulation testing market are primarily focusing on establishing strategic alliances to secure a competitive advantage. Strategic collaboration is a formal arrangement in which two or more entities come together to work towards specific, mutually beneficial targets. For example, in January 2023, Jana care, an American firm developing biomarker assays for its unique digital health platform, entered into a collaboration with Roche Diagnostics, a Swiss firm known for developing diagnostic tests, tools, and innovative healthcare solutions. The aim of this collaboration is to create and distribute a POC blood testing platform to screen for heart failure and chronic kidney disease. This revolutionary platform will allow patients to conduct blood tests at home, while the test results can be remotely examined by clinicians.
Major companies operating in the point-of-care (POC) coagulation testing market report are:
• AT&T Corporation
• Siemens Healthcare GmbH
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Medtronic Plc
• Koninklijke Philips N.V.
• Sysmex Corporation
• IDEXX Laboratories Inc.
• Quidel Corporation
• Bio-Rad Laboratories Inc.
• Teleflex Incorporated
• Werfen SA
• Nihon Kohden Corporation
• Horiba Ltd.
• Hycel
• Nova Biomedical Corporation
• Haemonetics Corporation
• Maccura Biotechnology Co. Ltd.
• Helena Laboratories Corporation
• Abaxis Inc.
• ARKRAY Inc.
• Radiometer Medical ApS
• HemoSonics LLC
• iLine Microsystems SL
• Corgenix Medical Corporation
• Quotient Limited
• Micropoint Bioscience Inc.
• Beijing Succeeder Technology Inc.
• EKF Diagnostics Holdings plc
North America was the largest region in the point-of-care (POC) coagulation testing market in 2024. The regions covered in the point-of-care (POC) coagulation testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.